Fulgent Genetics, Inc. (FLGT) Tops Q1 EPS by 73c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Fulgent Genetics Reports Record First Quarter Financial Results
May 6, 2021 4:05 PM EDTFirst Quarter 2021 Results:
Record Revenue of $359.4 million, growing more than 4,500% year-over-year Record Billable tests delivered approximately 3.8 million, or 290 times the volume of first quarter of 2020 Gross Margin improved approximately 32 percentage points year-over-year NGS Revenue grew 115% year-over-year Record GAAP income of $200.7 million, or $6.52 per share Record Non-GAAP income of $202.9 million, or $6.59 per share Record Adjusted EBITDA of $271.9 million Cash from operations of $233.2 million; Cash and investments of $697.4 million as of March 31, 20212021 Outlook:
Raises full year total revenue outlook to $830 million from $800 million,... More


